Skip to main content

Advertisement

SpringerLink
Log in

Treatment of osteoporosis in patients with chronic liver disease and in liver transplant recipients

  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

The pathogenesis of osteoporosis in chronic liver disease and post-liver transplantation is complex and heterogeneous. The development of hepatic osteodystrophy may be related to both increased bone resorption and decreased bone formation. Available medical treatments can be broadly classified into antiresorptive and bone-stimulating agents. Most published studies on the treatment of osteoporosis in patients with liver disease have used the commonly prescribed antiosteoporosis drugs approved for postmenopausal osteoporosis. These studies have included a small number of subjects and used bone mineral density (BMD) changes rather than fracture occurrence as an endpoint because of the short follow-up. Although the increases in BMD are promising, no intervention is proven to have antifracture efficacy in hepatic osteodystrophy. The natural history of bone disease following liver transplantation has not been fully investigated, although studies suggest that bone mineral loss is transient and generally reverses within a year following transplantation. The approach to treatment in liver transplant recipients should be targeted at preventing the early bone loss without interfering with the later recovery. Based on the available data, no single available agent can be considered as first-line therapy. In our opinion, the best treatment approach involves the elucidation of modifiable risk factors and the selection of agents targeted at the underlying derangements.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Bjoro K, Brandsaeter B, Wiencke K, et al.: Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease. Scand J Gastroenterol 2003, 38:320–327.

    Article  PubMed  CAS  Google Scholar 

  2. Diamond T, Stiel D, Lunzer M, et al.: Osteoporosis and skeletal fractures in chronic liver disease. Gut 1990, 31:82–87.

    PubMed  CAS  Google Scholar 

  3. Ninkovic M, Love SA, Tom B, et al.: High prevalence of osteoporosis in patients with chronic liver disease prior to liver transplantation. Calcif Tissue Int 2001, 69:321–326.

    Article  PubMed  CAS  Google Scholar 

  4. Ninkovic M, Skingle SJ, Bearcroft PW, et al.: Incidence of vertebral fractures in the first three months after orthotopic liver transplantation. Eur J Gastroenterol Hepatol 2000, 12:931–935.

    Article  PubMed  CAS  Google Scholar 

  5. Leidig-Bruckner G, Hosch S, Dodidou P, et al.: Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet 2001, 357:342–347.

    Article  PubMed  CAS  Google Scholar 

  6. Pares A, Guanabens N, Alvarez L, et al.: Collagen type Ialpha1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis. Hepatology 2001, 33:554–560.

    Article  PubMed  CAS  Google Scholar 

  7. Hay JE, Guichelaar MM: Evaluation and management of osteoporosis in liver disease. Clin Liver Dis 2005, 9:746–766. Comprehensive and up-to-date review on the pathogenesis and treatment of hepatic osteodystrophy.

    Article  Google Scholar 

  8. Monegal A, Navasa M, Guanabens N, et al.: Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif Tissue Int 1997, 60:148–154.

    Article  PubMed  CAS  Google Scholar 

  9. Janes CH, Dickson ER, Okazaki R, et al.: Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 1995, 95:2581–2586.

    Article  PubMed  CAS  Google Scholar 

  10. Gallego-Rojo FJ, Gonzalez-Calvin JL, Munoz-Torres M, et al.: Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 1998, 28:695–699.

    Article  PubMed  CAS  Google Scholar 

  11. Maalouf NM, Shane E: Osteoporosis after solid organ transplantation. J Clin Endocrinol Metab 2005, 90:2456–2465. [Published erratum appears in J Clin Endocrinol Metab 2005, 90:4118.] Concise review of osteoporosis following solid organ transplantation.

    Article  PubMed  CAS  Google Scholar 

  12. Guichelaar MM, Malinchoc M, Sibonga JD, et al.: Bone histomorphometric changes after liver transplantation for chronic cholestatic liver disease. J Bone Miner Res 2003, 18:2190–2199.

    Article  PubMed  Google Scholar 

  13. Feller RB, McDonald JA, Sherbon KJ, et al.: Evidence of continuing bone recovery at a mean of 7 years after liver transplantation. Liver Transpl Surg 1999, 5:407–413.

    Article  PubMed  CAS  Google Scholar 

  14. Hardinger KL, Ho B, Schnitzler MA, et al.: Serial measurements of bone density at the lumbar spine do not predict fracture risk after liver transplantation. Liver Transpl 2003, 9:857–862.

    Article  PubMed  Google Scholar 

  15. Braith RW, Mills RM, Welsch MA, et al.: Resistance exercise training restores bone mineral density in heart transplant recipients. J Am Coll Cardiol 1996, 28:1471–1477.

    Article  PubMed  CAS  Google Scholar 

  16. National Institutes of Health, Office of Dietary Supplements. Dietary supplement fact sheet: vitamin D. Available at: http://ods.od.nih.gov/factsheets/vitamind. asp. Accessed June 26, 2006.

  17. Holick MF: Vitamin D: the underappreciated D-lightful hormone that is important for skeletal and cellular health. Curr Opin Endocrinol Diabetes 2002, 9:87–98.

    Article  CAS  Google Scholar 

  18. Euvrard S, Kanitakis J: Skin cancers after liver transplantation: what to do? J Hepatol 2006, 44:27–32.

    Article  PubMed  Google Scholar 

  19. Pak CY, Avioli LV: Factors affecting absorbability of calcium from calcium salts and food. Calcif Tissue Int 1988, 43:55–60.

    Article  PubMed  CAS  Google Scholar 

  20. Camisasca M, Crosignani A, Battezzati PM, et al.: Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis. Hepatology 1994, 20:633–637.

    Article  PubMed  CAS  Google Scholar 

  21. Matloff DS, Kaplan MM, Neer RM, et al.: Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology 1982, 83:97–102.

    PubMed  CAS  Google Scholar 

  22. Herlong HF, Recker RR, Maddrey WC: Bone disease in primary biliary cirrhosis: histologic features and response to 25-hydroxyvitamin D. Gastroenterology 1982, 83:103–108.

    PubMed  CAS  Google Scholar 

  23. Mobarhan SA, Russell RM, Recker RR, et al.: Metabolic bone disease in alcoholic cirrhosis: a comparison of the effect of vitamin D2, 25-hydroxyvitamin D, or supportive treatment. Hepatology 1984, 4:266–273.

    PubMed  CAS  Google Scholar 

  24. Shiomi S, Masaki K, Habu D, et al.: Calcitriol for bone disease in patients with cirrhosis of the liver. J Gastroenterol Hepatol 1999, 14:547–552.

    Article  PubMed  CAS  Google Scholar 

  25. Neuhaus R, Kubo A, Lohmann R, et al.: Calcitriol in prevention and therapy of osteoporosis after liver transplantation. Transplant Proc 1999, 31:472–473.

    Article  PubMed  CAS  Google Scholar 

  26. Valero MA, Loinaz C, Larrodera L, et al.: Calcitonin and bisphosphonates treatment in bone loss after liver transplantation. Calcif Tissue Int 1995, 57:15–19.

    Article  PubMed  CAS  Google Scholar 

  27. Hay JE, Malinchoc M, Dickson ER: A controlled trial of calcitonin therapy for the prevention of post-liver transplantation atraumatic fractures in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 2001, 34:292–298.

    Article  PubMed  CAS  Google Scholar 

  28. Rossouw JE, Anderson GL, Prentice RL, et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002, 288:321–333.

    Article  PubMed  CAS  Google Scholar 

  29. Ormarsdottir S, Mallmin H, Naessen T, et al.: An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis. J Int Med 2004, 256:63–69.

    Article  CAS  Google Scholar 

  30. Crippin JS, Jorgensen RA, Dickson ER, et al.: Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. Am J Gastroenterol 1994, 89:47–50.

    PubMed  CAS  Google Scholar 

  31. Isoniemi H, Appelberg J, Nilsson CG, et al.: Transdermal oestrogen therapy protects postmenopausal liver transplant women from osteoporosis. A 2-year follow-up study. J Hepatol 2001, 34:299–305.

    Article  PubMed  CAS  Google Scholar 

  32. Levy C, Harnois DM, Angulo P, et al.: Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study. Liver Int 2005, 25:117–121.

    Article  PubMed  CAS  Google Scholar 

  33. Diamond T, Stiel D, Posen S: Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors? Ann Intern Med 1989, 110:430–436.

    PubMed  CAS  Google Scholar 

  34. Guanabens N, Pares A, Ros I, et al.: Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol 2003, 98:2268–2274.

    PubMed  CAS  Google Scholar 

  35. Musialik J, Petelenz M, Gonciarz Z: Effects of alendronate on bone mass in patients with primary biliary cirrhosis and osteoporosis: preliminary results after one year. Scand J Gastroenterol 2005, 40:873–874.

    Article  PubMed  Google Scholar 

  36. Millonig G, Graziadei IW, Eichler D, et al.: Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. Liver Transpl 2005, 11:960–966.

    Article  PubMed  Google Scholar 

  37. Crawford BA, Kam C, Pavlovic J, et al.: Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2006, 144:239–248.

    PubMed  CAS  Google Scholar 

  38. Hommann M, Abendroth K, Lehmann G, et al.: Effect of transplantation on bone: osteoporosis after liver and multivisceral transplantation. Transplant Proc 2002, 34:2296–2298.

    Article  PubMed  CAS  Google Scholar 

  39. Fan SL, Kumar S, Cunningham J: Long-term effects on bone mineral density of pamidronate given at the time of renal transplantation. Kidney Int 2003, 63:2275–2279.

    Article  PubMed  CAS  Google Scholar 

  40. Guanabens N, Pares A, del Rio L, et al.: Sodium fluoride prevents bone loss in primary biliary cirrhosis. J Hepatol 1992, 15:345–349.

    Article  PubMed  CAS  Google Scholar 

  41. Neer RM, Arnaud CD, Zanchetta JR, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434–1441.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Charles and Jane Pak Center for Mineral Metabolism and Clinical Research and Department of Internal Medicine, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, 75390-8885, Dallas, TX, USA

    Khashayar Sakhaee MD

Authors
  1. Naim M. Maalouf MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Khashayar Sakhaee MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maalouf, N.M., Sakhaee, K. Treatment of osteoporosis in patients with chronic liver disease and in liver transplant recipients. Curr Treat Options Gastro 9, 456–463 (2006). https://doi.org/10.1007/s11938-006-0002-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-006-0002-y

Keywords

Search

Navigation